Tag Archives: Drives

Incidence of Metabolic Conditions, CNS, and Cardiovascular Diseases Among Children Drives the Pediatric Drugs Market, According to New Report by Global Industry Analysts

May 24, 2012     No comments

San Jose, California (PRWEB) May 14, 2012

Follow us on LinkedIn ? The global pharmaceutical industry has always focused on the aging population, and the therapeutic drugs market for children has long been undervalued and underserved. However, the pediatric drugs market is currently emerging as an area of opportunity for drug manufacturers. Globally, about 26,500 children, aged below five years, die on a daily basis from preventable diseases. Pneumonia, Diarrhoea, Malaria, and AIDS are the major causes behind the high death toll in children. As a result, pediatric drugs market bodes tremendous opportunities for the pharmaceutical companies. Battered by the global economic downturn, the global pharmaceutical industry is beginning to see pediatric drugs sector as the ray of hope for increasing its profits. Segments such as anti-infectives, vaccines, and allergy and respiratory drugs, are fast emerging as profitable pediatric medicine segments. Moreover, changing lifestyles, and increasing instances of chronic conditions such as obesity, diabetes, and hypertension are also acting as growth propellers for the pediatric drugs market.

Over the years, children have long suffered as therapeutic orphans, witnessing problems such as lack of quality clinical trials, unlicensed medicines, appropriate information, and formulations. However, with the recent recognition and industry acceptance of distinct therapeutic needs for pediatric patients, initiation of regulatory programs has led to re-defining of norms for the pediatric industry. Several regulations, such as Best Pharmaceuticals for Children Act (BPCA), Pediatric Drug Research Equity Act (PREA), Food & Drug Administration Modernization Act (FDAMA), have been set up for rectifying flaws in the pediatric drugs market. Moreover, to encourage drug manufacturers for performing clinical trials for the pediatric population, the FDA and EMA have adopted new regulations. Several other factors are also driving growth of the pediatric drugs market, and the industry is expected to be one of the fastest growing drug markets in the ensuing years.

Sales in the pediatric drugs market are likely to surge in the following years, owing to the new approvals of numerous existing products, as well as the launch of new products, targeted mainly at children. Growth is primarily expected to emanate from pediatric vaccines, hormone therapy drugs, along with other segments such as respiratory and allergy products, CNS drugs, and anti-infective drugs. Further, sales of other drugs, including obesity medicines, are expected to grow, following their approval for pediatric use. Meanwhile, sales of OTC (Over-the-Counter) drugs are expected to remain stable, where growth is primarily expected to emanate from the increased use of popular products, such as OTC ibuprofen for children.

The US represents the largest regional market for pediatric drugs and vaccines globally, as stated by the new market research report on Pediatric Drugs and Vaccines. Europe trails behind the US market. However, growth in the market would be led by Asia-Pacific, which is projected to be the fastest growing regional market, and is forecast to witness a CAGR of more than 9.0% during the analysis period. Anti-infective Drugs represents the largest segment, while Pediatric Vaccines represents the fastest growing segment in the global pediatric drugs and vaccines market. Global market for Pediatric Hormones is forecast to grow at a CAGR of 6.6% during the analysis period.

Several innovative drug-delivery technologies are under development for facilitating easy administration of pediatric drugs, as taste and texture are major issues witnessed in the consumption of medicines by children. Moreover, to minimize the use of injections in children, various other needle-free, non-invasive alternatives such as inhalable formulations, thin-strip technologies, and transdermal patches, are prevalent.

Major players profiled in the report include Abbott Laboratories, Allergan Inc., AstraZeneca Plc., Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Merck Serono, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi, UCB Pharma, Shire Plc., among others.

The research report titled ?Pediatric Drugs and Vaccines: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the pediatric drugs and vaccines markets, current market trends, key growth drivers, overview of diseases in children, the prevalence, the treatment, insight into pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for pediatric drugs and vaccines market for years 2009 through 2017 for the following geographic markets – US, Europe, Asia-Pacific, Latin America, and Rest of World. The report analyses the market for pediatric drugs and vaccines market by the following segments ? Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Pediatric_Drugs_and_Vaccines_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Related Obesity Press Releases

Read More

Increasing Investment in Stem Cell Technology and Promising Research Outcomes Drives the Stem Cell Research Market, According to New Report by Global Industry Analysts

May 12, 2012     No comments

San Jose, California (PRWEB) May 10, 2012

Follow us on LinkedIn ? Stem cell research is a promising area of biotechnology, which holds tremendous potential in rendering a new approach to the treatment of various degenerative diseases. The area deals with employing regenerative stem cells for the replenishment of damaged cells of a particular organ or tissue with new cells. These repair blocks have created a new specialty in the area of medicine called the regenerative medicine. Stem cells hold potential to treat conditions such as Alzheimer?s disease, Parkinson?s disease, stroke, spinal cord injury, heart disease, diabetes, burns, rheumatoid arthritis and osteoarthritis. In addition to its therapeutic applications, stem cells are also finding use in drug discovery, promising new avenues in the area of drug development. Growth in the research space is attributed to the acceptance of stem cell technology by patients for treating chronic diseases. Moreover advancement in stem cell research can help reduce the escalating healthcare costs associated with conventional methods of treatment.

Stem cell technology is still in a nascent stage. The market still lacks substantial data that could establish its long-term efficacy as well as safety. Certain issues pertaining to its administration have also raised concerns. The regulatory and ethical barriers across the world, particularly in Western countries, are the major challenges ahead of stem cells research. The barriers are particularly more in embryonic stem cell research. On the other hand, countries such as India, with comparatively less opposition, are better positioned to conduct stem cell research. Lack of proper funding is also a matter of concern for stem cell research. Countries, such as Thailand, Taiwan, Malaysia, Singapore, China, and India, are engaged in commercial, clinical, and scientific advancements in stem cell research without proper funding.

Over the past few years, the stem cells market has witnessed several breakthroughs that bodes tremendous potential in reshaping the area of medicine. Potential therapeutic applications of stem cells cut across several debilitating and deadly disease areas, including cancer and AIDS. Stem cell research is entering new avenues of medicine, and promises to provide a solution to combat diseases that were hitherto believed to be incurable. There is a growing demand for such therapies, which in turn provokes continued investments in the area, and foretell a remarkable growth in the industry in the coming years. Presently, the field is focused upon the treatment of certain oncological ailments, which include non-Hodgkin’s lymphoma, multiple myeloma, and leukaemia. Additionally, non-cancerous diseases, including lupus, immunodeficiency, and aplastic anaemia, are also being investigated for treatment using stem cell technology.

Mesenchymal stem cells and hematopoietic stem cells, extracted from adult bone marrow, are the leading types of adult stem cells currently in demand in the area of medicine. Of these types, hematopoietic stem cells hold major share in disease management. The dominance of hematopoietic stem cells is in part due to the difficulty associated with the isolation of mesenchymal from the bone marrow owing to availability of cells in lower levels. The greatest strength of adult stem cells is the presence of genomic stability of a very high degree. Additionally, stem cell therapy does not necessitate pre-treatment or genetic modification that is required when dealing with embryonic stem cells.

The US represents the largest regional market worldwide, as stated by the new market research report on Stem Cell Research. Despite the 9-year ban, which ended in 2009, over federal funding for research in embryonic stem cells, North America is presently dominating the stem cell market. Key factors that have kept North American market on the top of the charts include advanced stem cell research infrastructure and facilities, and federal support for the research. Asia is emerging as the fastest growing regional market for stem cell research worldwide with countries such as Japan, China, Singapore, Korea, and Australia evolving as major hubs for stem cell research.

Major players profiled in the report include Advanced Cell Technology Inc., Athersys Inc., Cytori Therapeutics Inc., Genzyme Corporation, Geron Corporation, International Stem Cell Corporation, Mesoblast Ltd., Osiris Therapeutics Inc., StemCells Inc., ThermoGenesis Corp., among others.

The research report titled ?Stem Cell Research: A Global Strategic Business Report? announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, regulatory overview, overview on therapies under development, recent industry activity and profiles of market players worldwide. The report analyzes global adult stem cell research market in terms of annual investments in value for the years 2008 through 2017, for major geographic markets, including the US, Europe and Rest of World.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Stem_Cell_Research_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

Aging Population, Changing Lifestyles, and the Launch of New Drugs Drives the Global Pain Management Market, According to New Report by Global Industry Analysts, Inc.

May 11, 2012     No comments

San Jose, California (PRWEB) May 10, 2012

Follow us on LinkedIn ? Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. With increasing aged population and absence of a full-fledged pain management therapy, demand for better pain management therapies, addressing acute and chronic pain, is on the rise. The varied products used for pain management include non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, anticonvulsants, opioids, acetaminophen, tricyclic antidepressants, patient-controlled dosing, electrical stimulation as well as implants. Pain management therapeutics market is characterized by regular developments and discoveries of new drugs, addressing pain related health ailment issues, such as neuropathic pain, psychogenic pain, post-surgical pain, headache, backache, AIDS, and cancer. Moreover, higher demand for more efficient medical devices for pain treatment, and drugs continue to drive the pain management market.

The pain management business constitutes a major segment of the pharmaceutical industry. Pain management market is impacted by several factors, including emergence of pain management clinics, availability of generic versions of branded analgesics, and introduction of new drugs into the marketplace. Patent expiries of several leading NSAID drugs have created new opportunities for generic drugs to foray into the pain management market. The emergence of pain management clinics has critically impacted the overall pain management market worldwide. The market shows considerable growth prospects, regardless of the generic incursion for major products in the global market.

Presently, Lyrica, an anti-convulsant, and Cymbalta, an anti-depressant drug, are the significant drugs in the pain management market. With increasing incidences of pain arising from various conditions, the demand for pain management drugs is increasing, specifically in the developing nations. Safety and side effects are the major challenges confronted by drug developers. New compounds exhibiting high levels of efficacy and safety are likely to garner significant growth and capture a sizeable share of the market in the years to follow.

The US represents the largest regional market for pain management worldwide, followed by Europe, as stated by the new market research report on Pain Management. The US market for chronic and acute pain management therapies is currently driven by increasing aging population. The opioid and non-opioid pain management pharmaceuticals market holds immense potential due to the significant unmet medical needs in the pain treatment segment, along with the recall of Bextra and Vioxx. However, growth in the market would be led by Asia-Pacific, which is projected to be the fastest growing regional market during the 2009-2017 period. With increasing incidence of pain arising from various conditions, the demand for pain management drugs is increasing in the developing nations. Latin America is projected to post a compounded annual growth rate of close to 8.8% during the analysis period. Segment-wise, Pain Management Drugs represent the largest segment, while Pain Management Services constitute the fastest growing segment worldwide.

Dynamics of the pain management drugs market witnessed significant changes in the recent years. The failure of several drugs, considered initially as promising, including the recent unsuccessful COX-2 inhibitors, prompted manufacturers and researchers to undertake many research programs. Meanwhile, failure of COX-2 inhibitors led to a significant decline in R&D in COX-2 class and encouraged pharmaceutical companies to concentrate on other new targets. A considerable success is witnessed in the larger pharmaceutical companies employing genomic technologies in their research programs.

Major players profiled in the report include AstraZeneca Plc., Eli Lilly and Company, Endo Pharmaceuticals, GlaxoSmithkline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer Inc., Wyeth Inc., Sanofi, Purdue Pharma, among others.

The research report titled ?Pain Management: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the pain management market, current market trends, key growth drivers, overview of the major drug classes, insight into current leading and pipeline drugs, new product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for the pain management market for years 2009 through 2017 by the following geographic markets – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Pain_Management_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv